SARS-CoV-2 - Acalabrutinib - Candidats thérapeutiques

SARS-CoV-2 - Acalabrutinib - Candidats thérapeutiques


Acalabrutinib (or Calquence) is an inhibitor of Bruton's tyrosine kinase (BTK). By inactivating the BTK, acalabrutinib prevents activation of the B-cell antigen receptor (BCR) signaling pathway. The B cell activation and downstream survival pathways of B-cells are thus inhibited and, as a result, the growth of malignant B cells that overexpress B-cells is inhibited. It is for this mode of action that acalabrutinib is used in the treatment of certain types of non-Hodgkin's lymphoma such as mantle cell lymphoma.
A clinical trial is planned to evaluate the effect of acalabrutinib (Calquence) on the exaggerated immune response in patients with severe coronavirus 2019 infection (Covid-19). This clinical study was based on preliminary scientific and clinical data on the BTK pathway and its role in the production of inflammatory cytokines. The purpose of the study was to evaluate the efficacy of acalabrutinib in reducing mortality and ventilation support requirements for patients with severe symptoms of Covid-19.

Cat#
Description
Size
Price Excl. VAT
HY-17600-100mg
 100mg 
HY-17600-10mg
 10mg 
HY-17600-50mg
 50mg 
HY-17600-5mg
 5mg 
HY-17600-1mL
 10mM/1mL 
HY-17600-S
 0,5-1mg 
HY-17600-200mg
 200mg 
S3626-100mg
 100mg 
A115605-100mg
 100mg 
S3626-10mg
 10mg 
A115605-10mg
 10mg 
A115605-2.5mg
 2.5mg 
A115605-250mg
 250mg 
S3626-25mg
 25mg 
A115605-25mg
 25mg 
A115605-5mg
 5mg 
S3626-50mg
 50mg 
10-4806-25mg
 25 mg 
10-4806-5mg
 5 mg 
440755-2,5mg
 2.5mg 
440755-5mg
 5mg 
B1193-5
 5mg 
B1193-25
 25mg 
M5306-10mg
 10 mg 
M5306-50mg
 50 mg 
M5306-5mg
 5 mg 
474050-100mg
 100mg